PURPOSE: The response to neoadjuvant chemoradiotherapy (CRT) varies greatly in patients suffering from locally advanced rectal cancer. Our aim was to correlate the response to CRT with the pre-treatment expression of heat shock protein 90 (Hsp90), small heat shock protein 16.2 (sHsp 16.2), phospho-Akt (p-Akt), growth hormone-releasing hormone receptor (GHRH-R) and heme-binding protein 2 (SOUL) in order to try to identify one or more as a predictive marker. MATERIALS AND METHODS: Sixty-nine patients receiving combined CRT for locally advanced rectal cancer were examined retrospectively. Surgical resection was carried out 6-9 weeks following CRT. The histopathological response to neoadjuvant treatment was determined according to the modified Mandard score. Using immunohistochemistry, we investigated the relationship between the expression of the five cited proteins in the pre-operative samples as well as various clinical parameters and the histopathological regression of the tumors. RESULTS: Thirty-one patients (48%) were good responders, and 33 patients (52%) were found to respond poorly to neoadjuvant therapy. Among patients undergoing surgery 7 weeks following CRT, there were significantly more good responders than among patients who underwent surgery sooner (63% vs. 37%). High levels of expression of GHRH-R and Hsp90 were shown to be significantly correlated with minor or absent histological regression. CONCLUSIONS: GHRH-R and Hsp90 were found to be independent predictive factors of histopathological response to neoadjuvant RCT. Since GHRH-R antagonists and Hsp90 inhibitors are currently being tested as potential anticancer agents, our study implies the possible elaboration of an effective and individualized treatment of poor responders.
PURPOSE: The response to neoadjuvant chemoradiotherapy (CRT) varies greatly in patients suffering from locally advanced rectal cancer. Our aim was to correlate the response to CRT with the pre-treatment expression of heat shock protein 90 (Hsp90), small heat shock protein 16.2 (sHsp 16.2), phospho-Akt (p-Akt), growth hormone-releasing hormone receptor (GHRH-R) and heme-binding protein 2 (SOUL) in order to try to identify one or more as a predictive marker. MATERIALS AND METHODS: Sixty-nine patients receiving combined CRT for locally advanced rectal cancer were examined retrospectively. Surgical resection was carried out 6-9 weeks following CRT. The histopathological response to neoadjuvant treatment was determined according to the modified Mandard score. Using immunohistochemistry, we investigated the relationship between the expression of the five cited proteins in the pre-operative samples as well as various clinical parameters and the histopathological regression of the tumors. RESULTS: Thirty-one patients (48%) were good responders, and 33 patients (52%) were found to respond poorly to neoadjuvant therapy. Among patients undergoing surgery 7 weeks following CRT, there were significantly more good responders than among patients who underwent surgery sooner (63% vs. 37%). High levels of expression of GHRH-R and Hsp90 were shown to be significantly correlated with minor or absent histological regression. CONCLUSIONS:GHRH-R and Hsp90 were found to be independent predictive factors of histopathological response to neoadjuvant RCT. Since GHRH-R antagonists and Hsp90 inhibitors are currently being tested as potential anticancer agents, our study implies the possible elaboration of an effective and individualized treatment of poor responders.
Authors: Alexandre Havt; Andrew V Schally; Gabor Halmos; Jozsef L Varga; Gabor L Toller; Judit E Horvath; Karoly Szepeshazi; Frank Köster; Kevin Kovitz; Kate Groot; Marta Zarandi; Celia A Kanashiro Journal: Proc Natl Acad Sci U S A Date: 2005-11-18 Impact factor: 11.205
Authors: Jörg B Engel; Gunhild Keller; Andrew V Schally; Gabor L Toller; Kate Groot; Alexandre Havt; Patricia Armatis; Marta Zarandi; Jozsef L Varga; Gabor Halmos Journal: J Clin Endocrinol Metab Date: 2005-03-22 Impact factor: 5.958
Authors: Z Kahán; J L Varga; A V Schally; Z Rékási; P Armatis; L Chatzistamou; T Czömpöly; G Halmos Journal: Breast Cancer Res Treat Date: 2000-03 Impact factor: 4.872
Authors: Matthew F Kalady; Luiz Felipe de Campos-Lobato; Luca Stocchi; Daniel P Geisler; David Dietz; Ian C Lavery; Victor W Fazio Journal: Ann Surg Date: 2009-10 Impact factor: 12.969
Authors: Klaus Günther; Arno Dimmler; Franz Rödel; Udo Reulbach; Susanne Merkel; Birgit R Bittorf; Klaus E Matzel; Thomas Papadopoulos; Werner Hohenberger; Rolf Sauer; Claus Rödel Journal: J Surg Res Date: 2003-08 Impact factor: 2.192
Authors: Ferenc G Rick; Stephan Seitz; Andrew V Schally; Luca Szalontay; Awtar Krishan; Christian Datz; Andreas Stadlmayr; Stefan Buchholz; Norman L Block; Florian Hohla Journal: Cell Cycle Date: 2012-10-24 Impact factor: 4.534
Authors: Géza Mezey; Andrea Treszl; Andrew V Schally; Normann L Block; Laura Vízkeleti; Alíz Juhász; Almos Klekner; János Nagy; Margit Balázs; Gábor Halmos; László Bognár Journal: J Cancer Res Clin Oncol Date: 2014-06-01 Impact factor: 4.553
Authors: Laura Bognár; Ivett Hegedűs; Szabolcs Bellyei; Éva Pozsgai; László Zoltán; Katalin Gombos; Örs Péter Horváth; András Vereczkei; András Papp Journal: Infect Agent Cancer Date: 2018-11-29 Impact factor: 2.965
Authors: Laura Del Puerto-Nevado; Juan Pablo Marin-Arango; Maria Jesus Fernandez-Aceñero; David Arroyo-Manzano; Javier Martinez-Useros; Aurea Borrero-Palacios; Maria Rodriguez-Remirez; Arancha Cebrian; Teresa Gomez Del Pulgar; Marlid Cruz-Ramos; Cristina Carames; Begoña Lopez-Botet; Jesús Garcia-Foncillas Journal: BMC Cancer Date: 2016-07-25 Impact factor: 4.430